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Standard platform technologies for cell culture processing provide simple and robust strategies to meet rapid 
timelines for early process development and ease of manufacturing. However, when there is a need to achieve 
high antibody titers due to high product demand, both culture media and feed strategies must be customized for 
specific cell lines. Two case studies will describe the strategies employed as part of a process intensification 
effort to overcome the limitations of a platform Phase III cell culture process. The first case study will 
demonstrate an intensified fed-batch process development effort performed to maximize production of a CHO-
based monoclonal antibody, while maintaining product quality comparability with the original Phase III process. 
The second case study will describe the evaluation of a concentrated fed-batch process using alternating 
tangential flow filtration to retain the protein in the bioreactor, and achieve even higher titers in support of the 
high product demand forecast. These case studies will show that the intensified fed-batch process improved 
titers by 50%, and the concentrated fed-batch process improved titers by 100% relative to the fed-batch 
platform. 
 
